MicroRNA 298 (miR-298)

MicroRNA 298 (miR-298) is a regulatory non-coding RNA encoded by the MIR298 gene, involved in the post-transcriptional silencing of mRNA, chiefly through binding to complementary sequences in 3′ untranslated regions of target genes as part of the RNA-induced silencing complex (RISC)[1]. It has demonstrated effects in limiting the expression of amyloid precursor protein and BACE1, leading to reduced production of neurotoxic amyloid-β peptides and specific tau isoforms implicated in the pathogenesis of Alzheimer’s disease[1][2]. MiR-298 has also shown tumor suppressor activity in epithelial ovarian cancer, operating through suppression of EZH2, a polycomb protein[4]. Its involvement in metabolic and developmental processes has been suggested based on gene functions identified in murine systems[5]. Variations in miR-298 levels and gene SNPs have been linked to AD biomarkers, positioning it as a candidate for therapeutic intervention and as a biomarker for disease risk and progression[1][2][3].

Other names

MicroRNA 298hsa-mir-298MIR298MIRN298

Gene silencing through base pairing with 3′ UTR of target mRNAs, promoting degradation or translational repression. For Alzheimer’s disease: suppresses synthesis of APP, BACE1, and pathological tau via direct binding to mRNA. In cancer: targets and downregulates EZH2, leading to inhibition of cell migration and invasion.